Survival of 46 patients with AL amyloidosis ineligible for stem cell transplantation treated with M-Dex. (A) Progression-free (median, 3.8 years) and overall (median, 5.1 years) survival. (B) Effect of hematologic response on survival (6 months landmark). The median is 2.1 years for nonresponders versus not reached for responders (P < .001).